News
Oncoinvent presents 3Q company update in live webcast
Oncoinvent ASA: Grant of share options to new Chief Medical Officer
Oncoinvent appoints Dr Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin[®]
Invitation to business update - Wednesday 28 October 2026
Oncoinvent ASA - Cancellation of subsequent repair offering
Oncoinvent ASA – Disclosure of large shareholding
Oncoinvent ASA – Mandatory notification of trade – Return of lent shares following Private Placement
Oncoinvent ASA – New share capital registered
Oncoinvent to present three abstracts at EANM and ESMO 2026
